tabrecta
novartis europharm limited - capmatinib dihydrochloride monohydrate - krabbamein, lungnakrabbamein - Æxlishemjandi lyf - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.
asubtela (ethinylestradiol/drospirenon 0,03 mg/3 mg focus) filmuhúðuð tafla 3 mg/ 0,03 mg
exeltis healthcare s.l. - drospirenonum inn; ethinylestradiolum inn - filmuhúðuð tafla - 3 mg/ 0,03 mg
microgyn tafla
bayer ab* - levonorgestrelum inn; ethinylestradiolum inn - tafla
harmonet tafla 75 míkróg+ 20 míkróg
pfizer aps (p) - gestodenum inn; ethinylestradiolum inn - tafla - 75 míkróg+ 20 míkróg
cleodette filmuhúðuð tafla 3 mg/0,02 mg
teva b.v.* - drospirenonum inn; ethinylestradiolum inn - filmuhúðuð tafla - 3 mg/0,02 mg
melleva filmuhúðuð tafla 0,15 mg/0,03 mg
exeltis healthcare s.l. - levonorgestrelum inn; ethinylestradiolum inn - filmuhúðuð tafla - 0,15 mg/0,03 mg
mercilon tafla 150 míkróg/20 míkróg
n.v. organon* - desogestrelum inn; ethinylestradiolum inn - tafla - 150 míkróg/20 míkróg
microstad húðuð tafla 150 míkróg/30 míkróg
stada arzneimittel ag - levonorgestrelum inn; ethinylestradiolum inn - húðuð tafla - 150 míkróg/30 míkróg
nuvaring leggangainnlegg 0,120 mg/0,015 mg/24 klst.
n.v. organon* - etonogestrelum inn; ethinylestradiolum inn - leggangainnlegg - 0,120 mg/0,015 mg/24 klst.
ornibel leggangainnlegg 0,120mg / 0,015 mg/24 klst.
exeltis healthcare s.l. - etonogestrelum inn; ethinylestradiolum inn - leggangainnlegg - 0,120mg / 0,015 mg/24 klst.